Solid Lipid Nanoparticles: Promising Therapeutic Nanocarriers for Drug Delivery

Abstract

Development of colloidal delivery systems has opened new avenues/frontiers for improving drug delivery. Solid lipid nanoparticles have come up as the latest development in the arena of lipid based colloidal delivery systems after nanoemulsion and liposomes ever since their introduction in the early 1990s. In this review, the authors have made efforts to bring forth the essential and practically relevant aspects of SLNs. This review gives an overview of the preparation methods of solid lipid nanoparticles while mainly focussing on their biological applications including their projected applications in drug delivery. This review critically examines the influential factors governing the formation of SLNs and then discussing in detail the several techniques being utilized for their characterization. This review discusses the drug loading and drug release aspects of SLNs as these are useful biocompatible carriers of lipophilic and to a certain extent hydrophilic drugs. An updated list of drugs encapsulated into various lipids to prepare SLN formulations has been provided. Other relevant aspects pertaining to the clinical use of SLN formulations like their sterilization and storage stability have also been explained. A unique facet of this review is the discussion on the challenging issues of in vivo applications and recent progresses in overcoming these challenges which follows in the end.

RETRACTED ARTICLE: Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury

“…They are prepared mainly with phospholipids and solid lipids, which are generally considered safe, biocompatible, and biodegradable (Thukral et al, 2014;Misra et al, 2016). They can be a good alternative to polymeric systems due to their unique structure and properties, such as lower toxicity, the ability to protect active pharmaceutical ingredient from chemical degradation, and prolonged drug release.…”

Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers

“…25 SLNs combine the advantages of the traditional systems and avoid some of their major disadvantages, including controllable drug release, enhanced bioavailability of poorly water-soluble drugs, and alleviated drug efflux to overcome multidrug resistance. 26,27 NLCs, a new generation of SLNs, consist of a solid lipid matrix with a certain amount of liquid lipid.…”

Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles

“…20 SLNs are made from solid lipids with a mean diameter of 50 to 1,000 nm, which exhibit biocompatibility, physical stability, controlled release properties, and ease of manufacture. 21 SLN systems represent a promising platform both for conjugating PEG, thus achieving long circulation in vivo, and for incorporation of active targeting ligand.…”